Learning from COVID-19: How drug hunters can prepare for the next pandemic
Over 3 years, the SARS-CoV-2 pandemic killed nearly 7 million people and infected more
than 767 million globally. During this time, our very small company was able to contribute to …
than 767 million globally. During this time, our very small company was able to contribute to …
The need for speed and efficiency: a brief review of small molecule antivirals for COVID-19
While we currently have multiple highly effective vaccines approved for use against SARS-
CoV-2 in the USA and other countries, there are far fewer small molecule antivirals …
CoV-2 in the USA and other countries, there are far fewer small molecule antivirals …
C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps
Patients with severe COVID-19 develop acute respiratory distress syndrome (ARDS) that
may progress to cytokine storm syndrome, organ dysfunction, and death. Considering that …
may progress to cytokine storm syndrome, organ dysfunction, and death. Considering that …
SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads
We report here the synthesis and biological evaluation of a series of small molecule SARS-
CoV-2 PLpro inhibitors. We compared the activity of selected compounds in both SARS-CoV …
CoV-2 PLpro inhibitors. We compared the activity of selected compounds in both SARS-CoV …
Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm …
N Chandiwana, C Kruger, H Johnstone… - …, 2022 - thelancet.com
Background This exploratory study investigated four repurposed anti-infective drug
regimens in outpatients with COVID-19. Methods This phase 2, single centre, randomised …
regimens in outpatients with COVID-19. Methods This phase 2, single centre, randomised …
Vandetanib blocks the cytokine storm in SARS-CoV-2-infected mice
The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are
either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid …
either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid …
Computational and experimental approaches identify beta-blockers as potential SARS-CoV-2 spike inhibitors
Finding antivirals for SARS-CoV-2 is still a major challenge, and many computational and
experimental approaches have been employed to find a solution to this problem. While the …
experimental approaches have been employed to find a solution to this problem. While the …
Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
There are very few small-molecule antivirals for SARS-CoV-2 that are either currently
approved (or emergency authorized) in the US or globally, including remdesivir …
approved (or emergency authorized) in the US or globally, including remdesivir …
In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing
Abstract Background In November 2021, variant B. 1.1. 529 of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) was identified by the World Health Organization …
syndrome coronavirus 2 (SARS-CoV-2) was identified by the World Health Organization …
Arylamines QSAR-Based Design and Molecular Dynamics of New Phenylthiophene and Benzimidazole Derivatives with Affinity for the C111, Y268, and H73 Sites of …
G Sabadini, M Mellado, C Morales, J Mella - Pharmaceuticals, 2024 - mdpi.com
A non-structural SARS-CoV-2 protein, PLpro, is involved in post-translational modifications
in cells, allowing the evasion of antiviral immune response mechanisms. In this study …
in cells, allowing the evasion of antiviral immune response mechanisms. In this study …